DNA Link Inc Asset Resilience Ratio
DNA Link Inc asset resilience ratio. DNA Link Inc (127120) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 127120 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of DNA Link Inc (2012–2024)
Asset resilience ratio of DNA Link Inc from 2012 to 2024. This chart shows how DNA Link Inc's Asset Resilience Ratio has changed over time. See 127120 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down DNA Link Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is DNA Link Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩460.00 | 0.0% |
| Total Liquid Assets | ₩460.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: DNA Link Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
DNA Link Inc Industry Peers by Asset Resilience Ratio
Compare DNA Link Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 27.85% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
DNA Link Inc Asset Resilience Ratio by Year (2012–2024)
DNA Link Inc asset resilience ratio by year from 2012 to 2024. The table below shows the annual Asset Resilience Ratio data for DNA Link Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 8.49% | ₩4.62 Billion ≈ $3.13 Million |
₩54.39 Billion ≈ $36.86 Million |
-8.11pp |
| 2023-12-31 | 16.60% | ₩6.43 Billion ≈ $4.36 Million |
₩38.76 Billion ≈ $26.27 Million |
-6.72pp |
| 2022-12-31 | 23.32% | ₩10.15 Billion ≈ $6.88 Million |
₩43.51 Billion ≈ $29.48 Million |
-35.26pp |
| 2021-12-31 | 58.59% | ₩24.03 Billion ≈ $16.29 Million |
₩41.02 Billion ≈ $27.80 Million |
-12.22pp |
| 2020-12-31 | 70.81% | ₩37.21 Billion ≈ $25.21 Million |
₩52.54 Billion ≈ $35.61 Million |
+44.95pp |
| 2019-12-31 | 25.86% | ₩6.70 Billion ≈ $4.54 Million |
₩25.90 Billion ≈ $17.55 Million |
-10.69pp |
| 2018-12-31 | 36.55% | ₩12.82 Billion ≈ $8.69 Million |
₩35.07 Billion ≈ $23.76 Million |
+12.59pp |
| 2017-12-31 | 23.96% | ₩6.01 Billion ≈ $4.07 Million |
₩25.07 Billion ≈ $16.99 Million |
-5.64pp |
| 2016-12-31 | 29.60% | ₩7.65 Billion ≈ $5.19 Million |
₩25.86 Billion ≈ $17.53 Million |
+16.88pp |
| 2015-12-31 | 12.72% | ₩4.16 Billion ≈ $2.82 Million |
₩32.73 Billion ≈ $22.18 Million |
+11.59pp |
| 2014-12-31 | 1.13% | ₩231.00 Million ≈ $156.55K |
₩20.48 Billion ≈ $13.88 Million |
-15.52pp |
| 2012-12-31 | 16.65% | ₩5.00 Billion ≈ $3.39 Million |
₩30.03 Billion ≈ $20.35 Million |
-- |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more